Castagna Luca, Bramanti Stefania, Balzarotti Monica, Sarina Barbara, Todisco Elisabetta, Anastasia Antonella, Magagnoli Massimo, Mazza Rita, Nozza Andrea, Giordano Laura, Rodari Marcello, Rinifilo Eva, Chiti Arturo, Santoro Armando
Oncology and Haematology Department, Istituto Clinico Humanitas, Rozzano (MI), Italy.
Br J Haematol. 2009 May;145(3):369-72. doi: 10.1111/j.1365-2141.2009.07645.x. Epub 2009 Mar 5.
This retrospective study evaluated whether early 2-[fluorine-18]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) after two cycles of salvage chemotherapy (PET2) could predict survival after high-dose chemotherapy (HDC). Twenty-four Hodgkin lymphoma (HL) patients were included. PET2 was negative in 58% and positive in 42% of patients. Ninety per cent of patients (9/10) with positive PET2 relapsed after HDC while all but one patient with negative PET2 maintained a complete remission. The 2-year progression-free survival was 93% vs. 10% for patients with negative and positive PET2, respectively (P < 0.001). This study shows that interim PET can predict the outcome after high-dose chemotherapy in HL patients.
这项回顾性研究评估了在两个周期的挽救性化疗后进行早期2-[氟-18]氟-2-脱氧-D-葡萄糖正电子发射断层扫描（FDG-PET）（PET2）是否能够预测大剂量化疗（HDC）后的生存率。纳入了24例霍奇金淋巴瘤（HL）患者。PET2在58%的患者中为阴性，在42%的患者中为阳性。PET2阳性的患者中有90%（9/10）在HDC后复发，而PET2阴性的患者中除1例之外均维持完全缓解。PET2阴性和阳性患者的2年无进展生存率分别为93%和10%（P<0.001）。本研究表明，中期PET能够预测HL患者大剂量化疗后的结局。
